cancer
60 stories · Page 2 of 3
UCLA Can Grow Thousands of Cancer-Fighting Cell Doses in Six Weeks. Every Patient So Far Has Been a Mouse.
The lab put a $5,000-a-dose price on an off-the-shelf cancer therapy grown from cord blood that controlled tumors in mice with ovarian cancer and melanoma. No human has received it.
CancerSummit's $500 Million Lung Drug Split the Curve Patients Can't Feel
Ivonescimab delayed tumor progression by 2.4 months in EGFR-mutated lung cancer, but its overall-survival curve never cleared statistical significance and serious treatment-related adverse events nearly doubled.
CancerFused Into One Cell, a Neutrophil and a Macrophage Ate Tumors Two Ways
CAR-macrophage therapy keeps stalling in solid tumors: it can't get in, and it can't finish. Fuse a neutrophil onto it and, in mice, one dose shrank the tumor and kept it from coming back.
Drugs & FDAThe FDA Approved a Breast Cancer Drug Four Months After Its Advisers Voted No
On April 30 the FDA's oncology advisers voted 6 to 3 that AstraZeneca's camizestrant hadn't shown a clinically meaningful benefit. On September 4 the agency approved it anyway, conceding in its own approval that the benefit is "not yet confirmed."
CancerDecades of Cancer Warning Signs, and Still No Proof They Save Lives
England's cancer-awareness campaigns sent more people to the doctor for a decade. The reviews still can't show they caught a single cancer earlier or cut deaths, while the cancers that kill fastest stay silent until it's already too late.
CancerHigh Blood Sugar Hands Cancer Cells a Cloak the Immune System Can't See Through
Grown in a fluid built to mimic the human body, cancer cells used excess glucose to thicken a sugar coating that hid them from immune cells, an effect that never showed up in the standard lab dishes used across cancer biology.
Drugs & FDAThe Pancreatic-Cancer Pill That Doubles Survival: $39,800 a Month, and a Fast Lane Congress Never Approved
Rasonque roughly doubles median survival in metastatic pancreatic cancer. Revolution Medicines priced it at $477,600 a year, more than double Keytruda, and the FDA cleared it early through a voucher program lawmakers say Congress never authorized.
CancerA New Cancer 'Weapon' That Has Only Ever Slowed Tumors in Mice
Stanford's tissue-resident natural killer cells slowed melanoma and head-and-neck tumors in mice. John Sunwoo warned against reading too much into that. The coverage read plenty into it anyway.
CancerUC Irvine's 'Framework' for Safer CAR-T Is a Hypothesis Essay, Not a Study
The senior author consults for Kite Pharma, whose Yescarta accounted for all 6 grade-5 neurotoxicity deaths in the cited review's real-world data, the exact harm the paper proposes to treat.
CancerThe Cells That Heal Wounds Are Feeding Breast Cancer Its Nerves
University of Oklahoma researchers blocked the protein in mice and triple-negative tumors grew far less. In patients, all they have is a correlation and a drug, already sold for something else, that has never been tried against breast cancer.
CancerThe Cancer Trials That Buried Vitamin C Never Put It in a Vein
Mayo's famous trials gave advanced cancer patients vitamin C by mouth and found nothing. A randomized trial that delivered it by IV, at a dose pills cannot reach, doubled survival in metastatic pancreatic cancer.
Drugs & FDAThe FDA Twice Called This Melanoma Trial Uninterpretable. Then It Approved the Drug, at $450,000 a Course.
Federal reviewers rejected Replimune's melanoma therapy twice, faulting a single-arm trial they called not adequate and well-controlled and its results uninterpretable. No new controlled data ever answered them. After a 10-3 advisory vote, the FDA approved it anyway, at $450,000 a course.
Nutrition & FoodCancer Drugs Starve Tumors of Arginine. A Rockefeller Lab Says the Immune System May Need It to See Them.
Some cancer therapies deliberately strip arginine from the body to starve tumors. Rockefeller researchers found that in mice the same depletion can hide tumors, flu, and SARS-CoV-2 from the immune system.
CancerThe Reason Immunotherapy Bounces Off Prostate Cancer: Tumors Chew Off a Genetic Tail to Blind the Immune System
Prostate tumors overproduce a protein that destroys the immune system's docking targets. A CRISPR tool that blocks the trick made checkpoint drugs work again, so far only in mice.
CancerThe Genes Driving Cancer's Growth Are the Same Ones It Keeps Breaking
The same super-enhancers that make a tumor grow keep snapping its DNA, and the botched repairs are where the next mutations come from. The finding is real, careful, and already a year old.
CancerIn 2021, Creatine Spread Cancer in Mice. This Week, a UCLA Lab Said It Fights It.
A UCLA study found creatine energized cancer-fighting immune cells in mice and lab dishes. It was never tested in a patient, and a separate line of research says the same supplement feeds metastasis.
InvestigationsThe Phone-Radiation Study Everyone Called a Debunking Was Too Small to Find the Tumor
Japan and Korea spent two years 'validating' the NIH finding that cell-phone radiation gave rats heart tumors. They used one dose, one sex, and too few animals to detect it. Korea's rats grew the tumor anyway.
CancerA Week Instead of a Month: The Faster Prostate Radiation Was Only "As Safe" on the Coarser Ruler
PACE-C put five-fraction radiation against the four-week course in 1,208 men. On the old grading scale they matched. On the finer one the short course logged 17 percent bowel toxicity against 10 percent, and the trial still can't say whether the shorter beam controls cancer as well.
CancerThe Same Cancer Mutation, Opposite Effects: What 581 Mouse Tumors Say About Who Gets Sick
Cambridge and Yale gave four strains of mice one identical dose of a carcinogen. The tumors converged on the same pathway but took four different genetic routes to get there, and today's screening ignores the reason.
InvestigationsBPA Sits in 90% of Us. The Cancer Studies Sample It With a Method That Was Never Going to Find Anything.
Bisphenol A shows up in more than nine of ten Americans, yet California's reviewers just called the cancer evidence 'inadequate,' because the studies measure a chemical the body clears in hours from a single urine sample.
CancerThe Evolutionary Fix for Drug Resistance Works Best on a Tumor Too Small to Find
City St George's mathematicians say hitting a tumor at its weakest moment can drive it extinct. Their own model clears 95 percent only below 7 million cells, far smaller than any tumor a scan can find.
CancerPregnancy Stations Killer T Cells in the Milk Ducts, and a Decade Later They Haven't Left
Melbourne researchers found that pregnancy stations killer T cells in the milk ducts, where they persist for at least a decade and track with better breast cancer outcomes. Now the race is on to summon them with a hormone shot instead of a pregnancy.
CancerWhether a T Cell Keeps Killing Cancer or Quits Is Written in How Its Genome Folds
Exhausted CD8 T cells are why checkpoint drugs and CAR-T so often stall. New maps of the 3D genome show their fate is set by how the DNA is physically folded, and by CTCF, the protein that does the folding.
CancerOne Protein Keeps Your T Cells in the Fight. The Same Protein Feeds Autoimmune Disease.
In mice, deleting the LEF1 gene collapsed the reserve T cells that sustain the fight against chronic infection and cancer. The same deletion protected against autoimmune diabetes.